3 Telecom IT Services Provider, Pistons Gaskets and Cooling Parts Maker and Medicines Exporter Stocks With a Strong Future Roadmap: Tech Mahindra, Banco Products (India) and Sun Pharma
- November 17, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Tech Mahindra, Banco Products (India) and Sun Pharma: ROE of 13.7% to 28.6% and FY22 to FY26 revenue CAGR of 5.6% to 19.4%. Prices as of 16 Nov 2026.
Quick Answer
The three IT service, brake part and pharma stocks to watch are Tech Mahindra, Banco Products (India) and Sun Pharma. Their return on equity ranges from 13.7% to 28.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.6% to 19.4%. Banco Products (India) leads on both return on equity at 28.6% and revenue growth at 19.4% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.
IT service, brake part and pharma stocks offer a focused view of a sector where demand keeps widening. Tech Mahindra, Banco Products (India) and Sun Pharma cover an IT services company, an auto and industrial components maker and a pharmaceuticals company.
This list covers three IT service, brake part and pharma stocks with complete current figures: Tech Mahindra, Banco Products (India) and Sun Pharma. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are IT Service, Brake Part and Pharma Stocks?
IT service, brake part and pharma stocks are listed companies that provide IT and network services to telecom and global clients, make pistons, gaskets and cooling parts for vehicles and industry, and make medicines for India and global markets. Their earnings depend on client technology budgets, vehicle output and medicine demand.
IT Service, Brake Part and Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Tech Mahindra | 1,776.4 | 175,398 | 31.5 | 17.6 | 18.6 | 0.07 |
| Banco Products (India) | 673.9 | 8,345 | 16.9 | 35.2 | 28.6 | 0.36 |
| Sun Pharma | 1,867.5 | 422,283 | 34.9 | 36.2 | 13.7 | 0.06 |
On valuation, Banco Products (India) and Sun Pharma trade at a P/E below the industry P/E, while Tech Mahindra trades above it, which reflects the growth the market already expects. Readers comparing IT service, brake part and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do IT Service, Brake Part and Pharma Stocks Have a Strong Roadmap in India?
IT service, brake part and pharma stocks have a strong roadmap in India because rising client spending on digital work, steady vehicle output and strong demand for medicines keep widening the market for these companies.
- IT services. Telecom clients upgrade networks.
- Auto components. Vehicles need cooling and sealing parts.
- Pharmaceuticals. Patients need dependable medicines.
Why Tech Mahindra Features Among These IT Service, Brake Part and Pharma Stocks
Among the IT service, brake part and pharma stocks on this list, Tech Mahindra is a Mahindra Group technology services company that provides digital, network and enterprise services to clients in telecom, manufacturing, banking and other industries worldwide.
Revenue rose from Rs 45,758 crore in FY22 to Rs 56,847 crore in FY26, a compound annual growth rate of 5.6%. Net profit grew from Rs 2,397 crore in FY24 to Rs 4,806 crore in FY26, which works out to a compound annual growth rate of 41.6%.
The company has a return on equity of 18.6%, a debt to equity ratio of 0.07 and a market capitalisation of Rs 175,398 crore. The stock trades at a P/E of 31.5, above the industry P/E of 17.6.
Roadmap: The company is investing in artificial intelligence, cloud and 5G related services and deepening ties with large clients. Large deal wins in telecom and enterprise work support its pipeline.
What to watch: Track large deal wins, margin improvement and demand from telecom and enterprise clients.
Why Banco Products (India) Features Among These IT Service, Brake Part and Pharma Stocks
Among the telecom software, cooling parts and drug exporter shares on this list, Banco Products (India) is a Vadodara-based maker of engine cooling systems, radiators, heat exchangers, gaskets and sealing products for vehicle makers, industrial customers and the aftermarket.
The company has a return on equity of 28.6%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 8,345 crore. The stock trades at a P/E of 16.9, below the industry P/E of 35.2.
Revenue rose from Rs 1,963 crore in FY22 to Rs 3,995 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 152 crore in FY22 to Rs 482 crore in FY26, which works out to a compound annual growth rate of 33.3%. In the June 2026 quarter, revenue grew 20.9% year on year to Rs 1,190 crore, while net profit rose 11.7% to Rs 122 crore.
Roadmap: The company is growing its cooling systems range for commercial vehicles, off-highway machines and industrial uses and is widening its presence in overseas markets. Aftermarket sales add steady demand beyond new vehicle production.
What to watch: Monitor vehicle production trends, export orders and raw material costs.
Why Sun Pharma Features Among These IT Service, Brake Part and Pharma Stocks
Among the three companies on this list, Sun Pharmaceutical Industries is India’s largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.
Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%.
In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.
Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What to watch: Track specialty product launches, United States approvals and domestic prescription trends.
Tech Mahindra vs Banco Products (India) vs Sun Pharma on Key Financials
The table below sets the three IT service, brake part and pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Tech Mahindra | 45,758 | 56,847 | 5.6% | 4,806 | 8.5% |
| Banco Products (India) | 1,963 | 3,995 | 19.4% | 482 | 12.1% |
| Sun Pharma | 39,730 | 61,674 | 11.6% | 11,565 | 18.8% |
Banco Products (India) posts the highest return on equity in this group at 28.6%. Sun Pharma has the largest FY26 revenue at Rs 61,674 crore, and Banco Products (India) shows the fastest revenue growth with a 19.4% compound annual rate. A useful habit with IT service, brake part and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in IT Service, Brake Part and Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these IT service, brake part and pharma stocks, the main points are: Long-term telecom software, cooling parts and drug exporter shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Client spending. Technology budgets can vary with global conditions.
- Demand cycles. Sales can vary with seasons and rates.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter IT service, brake part and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on IT Service, Brake Part and Pharma Stocks
IT service, brake part and pharma stocks reward patient research into demand, execution and financial strength. Tech Mahindra, Banco Products (India) and Sun Pharma each have a clear plan to grow. Based on the 16 November 2026 close, Tech Mahindra trades at Rs 1,776.4, Banco Products (India) at Rs 673.9 and Sun Pharma at Rs 1,867.5. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these IT service, brake part and pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track IT service, brake part and pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are IT service, brake part and pharma stocks?
Ans. IT service, brake part and pharma stocks are listed companies that provide IT and network services to telecom and global clients, make pistons, gaskets and cooling parts for vehicles and industry, and make medicines for India and global markets. Their earnings depend on client technology budgets, vehicle output and medicine demand. This list looks at three of them, Tech Mahindra, Banco Products (India) and Sun Pharma, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.
Which IT service, brake part and pharma stocks are covered in this list?
Ans. This list covers Tech Mahindra, Banco Products (India) and Sun Pharma. Based on the 16 November 2026 close, Tech Mahindra traded at Rs 1,776.4, Banco Products (India) at Rs 673.9 and Sun Pharma at Rs 1,867.5. Their return on equity ranges from 13.7% to 28.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.6% to 19.4%.
Why do IT service, brake part and pharma stocks have a strong future roadmap in India?
Ans. IT service, brake part and pharma stocks have a strong roadmap in India because rising client spending on digital work, steady vehicle output and strong demand for medicines keep widening the market for these companies. The main drivers are as follows. IT services. Telecom clients upgrade networks. Auto components. Vehicles need cooling and sealing parts. Pharmaceuticals. Patients need dependable medicines. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Tech Mahindra performed financially?
Ans. Revenue rose from Rs 45,758 crore in FY22 to Rs 56,847 crore in FY26, a compound annual growth rate of 5.6%. Net profit grew from Rs 2,397 crore in FY24 to Rs 4,806 crore in FY26, which works out to a compound annual growth rate of 41.6%. The company has a return on equity of 18.6%, a debt to equity ratio of 0.07 and a market capitalisation of Rs 175,398 crore. The stock trades at a P/E of 31.5, above the industry P/E of 17.6. Looking ahead, the company is investing in artificial intelligence, cloud and 5G related services and deepening ties with large clients. Large deal wins in telecom and enterprise work support its pipeline.
How has Banco Products (India) performed financially?
Ans. Revenue rose from Rs 1,963 crore in FY22 to Rs 3,995 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 152 crore in FY22 to Rs 482 crore in FY26, which works out to a compound annual growth rate of 33.3%. In the June 2026 quarter, revenue grew 20.9% year on year to Rs 1,190 crore, while net profit rose 11.7% to Rs 122 crore. The company has a return on equity of 28.6%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 8,345 crore. The stock trades at a P/E of 16.9, below the industry P/E of 35.2. Looking ahead, the company is growing its cooling systems range for commercial vehicles, off-highway machines and industrial uses and is widening its presence in overseas markets. Aftermarket sales add steady demand beyond new vehicle production.
How has Sun Pharma performed financially?
Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What risks should investors check before buying IT service, brake part and pharma stocks?
Ans. Investors should check a few risks before buying IT service, brake part and pharma stocks. Client spending. Technology budgets can vary with global conditions. Demand cycles. Sales can vary with seasons and rates. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of IT service, brake part and pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.